BioAdaptives, Inc. (OTC: BDPT) has announced the upcoming commercial launch of XcellaraHeart, a cardiovascular wellness supplement designed to support heart health through a two-part strategy combining stem/progenitor cell mobilization with cardiovascular signaling support. The product is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August.
XcellaraHeart combines the company's Xcellara stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The Xcellara base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with zero adverse effects on more than twenty blood parameters. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology.
The company notes that a scientific evidence dossier detailing the formulation is available on the product website at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives' human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company's product-development rationale for combining the two.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com.
The launch of XcellaraHeart represents an expansion of BioAdaptives' product portfolio into the cardiovascular wellness space. By leveraging clinical data on stem cell mobilization and integrating a compound with known cardiovascular signaling properties, the company aims to address the growing consumer interest in heart health supplements. The availability of a scientific evidence dossier provides transparency and allows healthcare professionals and consumers to evaluate the rationale behind the formulation.
Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, and dietary supplements that support heart health are a significant market segment. XcellaraHeart's approach, which targets stem cell mobilization and cardiovascular repair pathways, distinguishes it from conventional supplements that focus on cholesterol or blood pressure management. The company's emphasis on clinical evidence may appeal to consumers seeking scientifically backed products.
For additional information about BioAdaptives and its products, visit the company's website at www.bioadaptives.com.
